What Can You Expect at the Investigative & Preclinical Toxicology Forum in 2026?
The Investigative & Preclinical Toxicology Summit is the only industry-led forum dedicated to advancing predictive toxicology across in vivo, in vitro, and in silico models at a time when biopharma is under increasing pressure to reduce late-stage failure and rethink traditional safety strategies. With nearly one-third of clinical attrition driven by toxicity, and regulatory agencies actively encouraging the adoption of New Approach Methodologies (NAMs), this meeting arrives at a critical inflection point for toxicologists, safety scientists, and translational leaders across pharma and biotech.
What to Expect?
Across two focused conference days and interactive pre-conference workshops, the summit delivers practical, data-driven insights on model selection, validation, and regulatory positioning, spanning investigative toxicology, microphysiological systems (MPS), organoids, virtual control groups, AI-enabled toxicology, and human-relevant dose selection. Attendees will benchmark what is working today versus what still fails in the clinic, learn directly from FDA-experienced speakers, IQ MPS and VICT3R collaborators, and explore how to build confidence in NAMs without overpromising translatability.
Designed by and for the industry, this event equips toxicology leaders with the tools, frameworks, and cross-functional perspectives needed to de-risk development earlier, improve IND success, reduce animal use, and translate safety signals into clinically meaningful decisions - making it an essential meeting for anyone shaping the future of modern toxicology and regulatory science.
Unmissable Event Highlights
Benchmarking Predictive Toxicology at a Regulatory Inflection Point
Gain clarity on what regulators expect as the FDA accelerates the shift away from traditional animal testing. Hear real-world case studies from IQ MPS affiliates, VICT3R reps, and pharma leaders on how NAMs,in vitro models, and computational toxicology are being positioned, reviewed, and accepted in IND-enabling safety packages.
Smarter Model Selection Across In Vivo, In Vitro & In Silico
Move beyond one-size-fits-all toxicology. Learn how leading biopharma teams are integrating structural alerts, organoids, MPS, virtual control groups (with VICT3R), and AI-enabled models to select the safest candidates earlier, prioritize risk, and reduce costly late-stage failures across small molecules and complex biologics.
Translating Mechanistic Signals into Human-Relevant Safety Decisions
Explore how high-content and mechanistic models including liver phenotypic assays, lung-on-a-chip systems, GI organoids, and ADC-specific platforms are being used to bridge the gap between preclinical findings and clinical outcomes. Understand where translation is strongest, where it still breaks down, and how to interpret safety signals with confidence.
Validation, Trust & Collaboration to Accelerate Adoption of NAMs
Hear directly from pharma, consortia, and AI leaders on how to validate new models without over-claiming, define fit-for-purpose use, and build trust through benchmarking and data sharing. Learn how initiatives like IQ MPS and VICT3R are aligning industry, regulators, and technology developers to accelerate adoption while maintaining scientific rigor.
Explore the Full Event Guide
- Hear from 50+ toxicology leaders from pharma, biotech, FDA & global consortia sharing real-world IND and model validation experience
- Featuring 2 pre-conference workshops deep-diving into regulatory strategy, NAMs validation, and translational drug development decision-making
- Discover end-to-end coverage of NAMs from in vitro & MPS to in silico and virtual control groups, benchmarked against in vivo data
- High-value networking with decision-makers through roundtables, panels, and structured networking sessions
- Learn about case-driven sessions across modalities, including ADCs, bispecifics, cell therapy, radio-conjugates, and small molecules
Attending Companies Include
Explore the Scientific Agenda
Dive into a highly practical program benchmarking in vivo, in vitro, and in silico toxicology models, with real-world case studies on NAM validation, regulatory strategy, dose selection, and human-relevant translation.
Partner With Toxicology Leaders
Position your solutions at the center of industry decision-making as pharma and biotech actively evaluate next-generation CRO services, NAM platforms, AI tools, and translational models to reduce risk and accelerate IND success.
Join Toxicology Decision-Makers
Connect with investigative, translational, preclinical, and regulatory toxicologists from the top biopharma companies through focused workshops, panels, and networking designed to spark meaningful scientific and commercial conversations.